Verastem $VSTM is getting its proverbial second chance.
Once battered, bruised and left on the ropes after the complete failure of the initial strategy mapped by Christoph Westphal, the executive team at Verastem snapped up a tarnished star as Infinity happily handed off its perfectly approvable — but commercially unexciting — PI3K drug duvelisib for exactly nothing up front.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,